Ilyang Pharm (007570) — Cash Flow Quality Index
Ilyang Pharm (007570) has a Cash Flow Quality Index of 3.92x as of June 2025. Operating cash flow of ₩2.26 Billion exceeds net income of ₩576.52 Million, indicating high earnings quality where cash backs reported profits. Explore 007570 long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Ilyang Pharm Cash Flow Quality Index (2003–2024)
Historical Cash Flow Quality Index for Ilyang Pharm across 11 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check Ilyang Pharm tangible book value ratio to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for Ilyang Pharm (2003–2024)
Year-by-year earnings quality comparison for Ilyang Pharm. For live market cap and the full company financial profile, see 007570 stock market capitalisation.
| Year | Quality Index | Operating CF (KRW) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | 0.55x | ₩5.61 Billion | ₩10.26 Billion | ▼ -52.7% |
| 2023 | 1.16x | ₩13.34 Billion | ₩11.52 Billion | ▼ -25.6% |
| 2022 | 1.56x | ₩29.94 Billion | ₩19.24 Billion | ▼ -66.6% |
| 2021 | 4.66x | ₩67.02 Billion | ₩14.38 Billion | ▼ -11.8% |
| 2020 | 5.28x | ₩57.48 Billion | ₩10.88 Billion | ▲ +45.8% |
| 2019 | 3.62x | ₩36.19 Billion | ₩9.98 Billion | ▼ -24.4% |
| 2017 | 4.79x | ₩30.03 Billion | ₩6.26 Billion | ▲ +4.9% |
| 2016 | 4.57x | ₩26.98 Billion | ₩5.91 Billion | ▼ -50.0% |
| 2015 | 9.13x | ₩40.27 Billion | ₩4.41 Billion | ▲ +1292.2% |
| 2013 | -0.77x | ₩-3.04 Billion | ₩3.96 Billion | ▼ -108.5% |
| 2003 | 9.01x | ₩10.08 Billion | ₩1.12 Billion | — |